You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 8,772,353

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,772,353 protect, and when does it expire?

Patent 8,772,353 protects OSPHENA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-one countries.

Summary for Patent: 8,772,353

Patent landscape, scope, and claims:

Title:	Method for enhancing the bioavalability of ospemifene
Abstract:	This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s):	Anttila; Markku (Turku, FI)
Assignee:	Hormos Medical Ltd. (Turku, FI)
Application Number:	13/904,818
Patent Claim Types: see list of patent claims	Use; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,772,353

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	AB	RX	Yes	Yes	8,772,353	⤷ Subscribe				TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE	⤷ Subscribe
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	AB	RX	Yes	Yes	8,772,353	⤷ Subscribe				TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE	⤷ Subscribe
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	AB	RX	Yes	Yes	8,772,353	⤷ Subscribe				TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,772,353

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1713458	⤷ Subscribe	CA 2015 00031	Denmark	⤷ Subscribe
European Patent Office	1713458	⤷ Subscribe	C300742	Netherlands	⤷ Subscribe
European Patent Office	1713458	⤷ Subscribe	92736	Luxembourg	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.